VLP COVID-19 vaccine (Saiba Biotech)

VLP COVID-19 vaccine (Saiba Biotech) is a preclinical vaccine candidate developed to prevent COVID-19. It utilizes Saiba Biotech's proprietary virus-like particle (VLP) platform to display SARS-CoV-2 antigens, such as the spike protein or its receptor-binding domain (RBD), in a highly repetitive and organized array. This structure mimics the physical form of the actual virus, which effectively stimulates the immune system to produce high titers of neutralizing antibodies and activate robust T-cell responses without the risk of infection. The development of this vaccine involves collaborations with several prominent institutions, including the University of Zurich, the Jenner Institute at the University of Oxford, ETH Zurich, and A*STAR Singapore.

Other names

SARS-CoV-2 VLP vaccineSARS-CoV2 VLP vaccineSARS-CoV 2 VLP vaccineSARS-CoV-2 VLP-based vaccineSARS-CoV2 VLP-based vaccineSARS-CoV 2 VLP-based vaccinevirus-like particle COVID-19 vaccine-Saiba Biotech-SARS-CoV-2 antigens-VLP-based vaccine-COVID-19